

1. Record Nr.	UNINA9910968977103321
Titolo	Reaping the benefits of genomic and proteomic research : intellectual property rights, innovation, and public health // Committee on Intellectual Property Rights in Genomic and Protein Research and Innovation, Board on Science, Technology, and Economic Policy, Committee on Science, Technology, and Law Policy and Global Affairs, National Research Council of the National Academies ; Stephen A. Merrill and Anne-Marie Mazza, editors
Pubbl/distr/stampa	Washington, D.C., : National Academies Press, c2006
ISBN	9786610447220 9780309164887 0309164885 9781280447228 1280447222 9780309655231 0309655234
Edizione	[1st ed.]
Descrizione fisica	1 online resource (188 p.)
Altri autori (Persone)	MerrillStephen A MazzaAnne-Marie
Disciplina	572.8
Soggetti	Genomics - United States Proteomics - United States Intellectual property - United States
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references (p. 150-154).
Nota di contenuto	""Front Matter""; ""Preface and Acknowledgments""; ""Contents""; ""List of Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Genomics, Proteomics, and the Changing Research Environment""; ""3 The U.S. Patent System, Biotechnology, and the Courts""; ""4 Trends in the Patenting and Licensing of Genomic and Protein Inventions and Their Impact on Biomedical Research""; ""5 Conclusions and Recommendations""; ""References""; ""Appendixes""; ""Appendix A Biographical Information of Committee and Staff""; ""Appendix B Search

## Algorithms Used to Identify Patents of Interest""

---

### Sommario/riassunto

The patenting and licensing of human genetic material and proteins represents an extension of intellectual property (IP) rights to naturally occurring biological material and scientific information, much of it well upstream of drugs and other disease therapies. This report concludes that IP restrictions rarely impose significant burdens on biomedical research, but there are reasons to be apprehensive about their future impact on scientific advances in this area. The report recommends 13 actions that policy-makers, courts, universities, and health and patent officials should take to prevent the increasingly complex web of IP protections from getting in the way of potential breakthroughs in genomic and proteomic research. It endorses the National Institutes of Health guidelines for technology licensing, data sharing, and research material exchanges and says that oversight of compliance should be strengthened. It recommends enactment of a statutory exception from infringement liability for research on a patented invention and raising the bar somewhat to qualify for a patent on upstream research discoveries in biotechnology. With respect to genetic diagnostic tests to detect patient mutations associated with certain diseases, the report urges patent holders to allow others to perform the tests for purposes of verifying the results.

---